JP2002512029A - ヒトk+イオンチャンネルおよびその治療的適用 - Google Patents

ヒトk+イオンチャンネルおよびその治療的適用

Info

Publication number
JP2002512029A
JP2002512029A JP2000544795A JP2000544795A JP2002512029A JP 2002512029 A JP2002512029 A JP 2002512029A JP 2000544795 A JP2000544795 A JP 2000544795A JP 2000544795 A JP2000544795 A JP 2000544795A JP 2002512029 A JP2002512029 A JP 2002512029A
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
cells
cell
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000544795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512029A5 (cg-RX-API-DMAC7.html
Inventor
アンゲル パルド−フェルナンデス,ルイス
ステューマー,ヴァルター
ベック,シンネーヴェ
ブリュッゲマン,アンドレア
カミノ フェルナンデス−ミランダ,ドナート デル
ペレス,アラケリ サンチェス
ヴェゼロー,リュディガー
Original Assignee
マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー.ファウ.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー.ファウ. filed Critical マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー.ファウ.
Publication of JP2002512029A publication Critical patent/JP2002512029A/ja
Publication of JP2002512029A5 publication Critical patent/JP2002512029A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000544795A 1998-04-21 1999-04-21 ヒトk+イオンチャンネルおよびその治療的適用 Withdrawn JP2002512029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98107268.9 1998-04-21
EP98107268 1998-04-21
PCT/EP1999/002695 WO1999054463A2 (en) 1998-04-21 1999-04-21 Human k+ ion channel and therapeutic applications thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009160236A Division JP2009235091A (ja) 1998-04-21 2009-07-06 ヒトk+イオンチャンネルおよびその治療的適用

Publications (2)

Publication Number Publication Date
JP2002512029A true JP2002512029A (ja) 2002-04-23
JP2002512029A5 JP2002512029A5 (cg-RX-API-DMAC7.html) 2006-06-15

Family

ID=8231794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000544795A Withdrawn JP2002512029A (ja) 1998-04-21 1999-04-21 ヒトk+イオンチャンネルおよびその治療的適用
JP2009160236A Pending JP2009235091A (ja) 1998-04-21 2009-07-06 ヒトk+イオンチャンネルおよびその治療的適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009160236A Pending JP2009235091A (ja) 1998-04-21 2009-07-06 ヒトk+イオンチャンネルおよびその治療的適用

Country Status (10)

Country Link
US (7) US6638736B1 (cg-RX-API-DMAC7.html)
EP (1) EP1073738B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002512029A (cg-RX-API-DMAC7.html)
AT (1) ATE278017T1 (cg-RX-API-DMAC7.html)
CA (1) CA2323571A1 (cg-RX-API-DMAC7.html)
DE (1) DE69920681T2 (cg-RX-API-DMAC7.html)
DK (1) DK1073738T3 (cg-RX-API-DMAC7.html)
ES (1) ES2230852T3 (cg-RX-API-DMAC7.html)
PT (1) PT1073738E (cg-RX-API-DMAC7.html)
WO (1) WO1999054463A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520186A (ja) * 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類eag1イオンチャネルタンパク質に対する新規の抗体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1073738E (pt) * 1998-04-21 2005-01-31 Max Planck Ges Forderung Der W Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas
DE10025620A1 (de) * 2000-05-24 2001-12-06 Forschungsgesellschaft Genion Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten
DE10224534A1 (de) * 2002-05-31 2003-12-11 Juergen Dolderer Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung
WO2006037611A2 (en) * 2004-10-01 2006-04-13 Centro De Investigación Y De Estudios Avanzados Del Ipn Methods for the early diagnosis of viral infections, inflammatory diseases, a predisposition for proliferative disorders or hyperplasia by analysing eag or erg expression levels
AU2013201604B2 (en) * 2007-04-13 2014-08-14 Southern Research Institute Anti-angiogenic agents and methods of use
ES2334084B1 (es) * 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
TWI570415B (zh) * 2015-10-02 2017-02-11 A spring probe having an outer sleeve and a probe device having the spring probe
EP3195727A1 (en) 2016-01-22 2017-07-26 Forschungsinstitut Fur Biologischen Landbau (FiBL) Duddingtonia flagrans strain and feed additive formulation for biological pest control

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000168A1 (en) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
US6610827B1 (en) * 1997-10-29 2003-08-26 Elan Pharmaceuticals, Inc. Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
PT1073738E (pt) * 1998-04-21 2005-01-31 Max Planck Ges Forderung Der W Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000168A1 (en) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520186A (ja) * 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類eag1イオンチャネルタンパク質に対する新規の抗体

Also Published As

Publication number Publication date
US7129207B2 (en) 2006-10-31
ES2230852T3 (es) 2005-05-01
WO1999054463A3 (en) 2000-04-20
CA2323571A1 (en) 1999-10-28
ATE278017T1 (de) 2004-10-15
PT1073738E (pt) 2005-01-31
US6638736B1 (en) 2003-10-28
DE69920681T2 (de) 2005-09-08
US20080020406A1 (en) 2008-01-24
US7364730B2 (en) 2008-04-29
US7314914B2 (en) 2008-01-01
EP1073738A2 (en) 2001-02-07
US20030077735A1 (en) 2003-04-24
DE69920681D1 (de) 2004-11-04
US7364845B2 (en) 2008-04-29
DK1073738T3 (da) 2005-01-24
WO1999054463A2 (en) 1999-10-28
EP1073738B1 (en) 2004-09-29
US20030087377A1 (en) 2003-05-08
US20030087378A1 (en) 2003-05-08
JP2009235091A (ja) 2009-10-15
US20030092120A1 (en) 2003-05-15
US20100021467A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
JP2009235091A (ja) ヒトk+イオンチャンネルおよびその治療的適用
US20130030039A1 (en) Novel multidrug resistance-associated polypeptide
JP2002514055A (ja) ガラニンgalr3受容体をコードするdnaおよびその使用
US20020187947A1 (en) Inflammation-related gene
US6617450B1 (en) P-glycoproteins and uses thereof
JP2002536989A (ja) ガラニン受容体と類似したgタンパク質共役受容体
AU782848B2 (en) DNA encoding SNORF62 and SNORF72 receptors
Mihovilovic et al. Expression of mRNAs in human thymus coding for the α3 subunit of a neuronal acetylcholine receptor
US5288621A (en) Pituitary TRH receptor
EP1220911B1 (en) P-glycoproteins and uses thereof
US6855812B2 (en) P-glycoproteins and uses thereof
US20030040476A1 (en) EAG gene
AU2004202022A1 (en) Human N-type calcium channel isoform and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110302

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628